Kv2.2-Derived Peptides Block Kv2.1 Channel Insertion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic stroke lack FDA-approved neuroprotective drugs that can mitigate irreversible neuronal cell loss, with existing therapies focusing on reperfusion rather than addressing the underlying neuronal damage caused by excitotoxic injury and delayed apoptosis.
Innovation Solution
Development of peptides derived from the C-terminal region of the voltage-gated potassium channel Kv2.2 that induce declustering of the cognate potassium channel Kv2.1, blocking pro-apoptotic potassium channel membrane insertion and preventing cytoplasmic ion loss, thereby preserving neuronal cell viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If thrombolytic therapy and surgical endovascular interventions are used to achieve brain reperfusion, then blood flow is restored following ischemia, but irreversible neuronal cell loss occurs due to excitotoxic injury and delayed apoptosis
Solution Approach 1:
The patent applies preliminary action by administering the Kv2.1 channel-blocking peptide before delayed apoptosis occurs (within 3-6 hours of ischemia). This timing intercepts the apoptotic pathway before it executes irreversible neuronal death, allowing reperfusion to proceed while preventing the subsequent cell loss that would otherwise occur
Solution Approach 2:
The patent uses an intermediary substance—the peptide derived from Kv2.2 C-terminus—that blocks Kv2.1 channel activity. This intermediary mediates between the reperfusion process and neuronal survival by preventing pro-apoptotic potassium efflux through Kv2.1 channels, thereby protecting neurons from death despite restored blood flow
2Productivity
If Kv2.1 channel membrane insertion is allowed to proceed, then neuronal apoptosis is facilitated through potassium efflux, but neuroprotection is reduced
Solution Approach 1:
The patent applies preliminary anti-action by blocking Kv2.1 channel membrane insertion and activity before pro-apoptotic potassium efflux can occur. The peptide prevents the channel from mediating neuronal death, thereby counteracting the apoptotic pathway at its origin rather than attempting to reverse it after damage occurs
Solution Approach 2:
The patent extracts or removes the harmful function of Kv2.1 channels by selectively blocking their pro-apoptotic activity. The peptide derived from Kv2.2 C-terminus specifically targets and inhibits Kv2.1 channel membrane insertion and potassium efflux, separating the harmful apoptotic function from the channel's normal physiological roles
Data Source
AI summary
Neuroprotective peptides derived from the voltage-gated potassium channel Kv2.2 are described. The peptides promote dispersal of the cognate channel Kv2.1 in neurons, thereby blocking pro-apoptotic potassium efflux, and preserving cell viability after apoptotic injury. Methods of preventing and treating neuronal damage, such as neuronal damage following ischemic stroke, by administering the neuroprotective peptides are described. Fusion of the neuroprotective peptides to a cell-penetrating peptide to promote cellular uptake is also described.